File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomised controlled trial of recombinant interferon-γ in Chinese patients with chronic hepatitis B virus infection

TitleA randomised controlled trial of recombinant interferon-γ in Chinese patients with chronic hepatitis B virus infection
Authors
Issue Date1991
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763
Citation
Journal Of Medical Virology, 1991, v. 34 n. 3, p. 184-187 How to Cite?
AbstractNineteen Chinese patients with chronic hepatitis B virus (HBV) infection, seropositive for HBV e antigen (HBeAg) and HBV DNA on at least three occasions in 6 months, were randomised to receive either recombinant human interferon-gamma (rIFNγ) 0.1 mg/m2 intramuscularly thrice weekly for 16 weeks (n = 11) or no anti-viral therapy (controls, n = 8). Five patients in the treatment group and four patients in the control group had persistently elevated serum alanine aminotransferases (ALT) of over two times the upper limit of normal before entering into the trial. rIFNγ had no or minimal inhibitory effect on serum HBV DNA during treatment and no patient developed e-seroconversion or sustained loss of serum HBV DNA. Hepatitic flare, which occurred in a proportion of patients responding successfully to interferon-α (IFNα) therapy, was not observed with rIFNγ treatment. Side-effects included pyrexia and mild headache that showed tachyphylaxis and were well tolerated by all patients. In the control group, one patient with elevated pre-entry serum ALT lost serum HBV DNA and seroconverted to anti-HBe. Another patient with elevated ALT lost serum HBV DNA transiently during therapy. In the dose given, rIFNγ was safe but had no apparent anti-viral effects in Chinese patients with chronic HBV infection.
Persistent Identifierhttp://hdl.handle.net/10722/161880
ISSN
2015 Impact Factor: 1.998
2015 SCImago Journal Rankings: 1.015
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, JYNen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorChung, HTen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLin, HJen_US
dc.date.accessioned2012-09-05T05:15:44Z-
dc.date.available2012-09-05T05:15:44Z-
dc.date.issued1991en_US
dc.identifier.citationJournal Of Medical Virology, 1991, v. 34 n. 3, p. 184-187en_US
dc.identifier.issn0146-6615en_US
dc.identifier.urihttp://hdl.handle.net/10722/161880-
dc.description.abstractNineteen Chinese patients with chronic hepatitis B virus (HBV) infection, seropositive for HBV e antigen (HBeAg) and HBV DNA on at least three occasions in 6 months, were randomised to receive either recombinant human interferon-gamma (rIFNγ) 0.1 mg/m2 intramuscularly thrice weekly for 16 weeks (n = 11) or no anti-viral therapy (controls, n = 8). Five patients in the treatment group and four patients in the control group had persistently elevated serum alanine aminotransferases (ALT) of over two times the upper limit of normal before entering into the trial. rIFNγ had no or minimal inhibitory effect on serum HBV DNA during treatment and no patient developed e-seroconversion or sustained loss of serum HBV DNA. Hepatitic flare, which occurred in a proportion of patients responding successfully to interferon-α (IFNα) therapy, was not observed with rIFNγ treatment. Side-effects included pyrexia and mild headache that showed tachyphylaxis and were well tolerated by all patients. In the control group, one patient with elevated pre-entry serum ALT lost serum HBV DNA and seroconverted to anti-HBe. Another patient with elevated ALT lost serum HBV DNA transiently during therapy. In the dose given, rIFNγ was safe but had no apparent anti-viral effects in Chinese patients with chronic HBV infection.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763en_US
dc.relation.ispartofJournal of Medical Virologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshDrug Toleranceen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Blood - Epidemiology - Therapyen_US
dc.subject.meshHepatitis, Chronic - Blood - Epidemiology - Therapyen_US
dc.subject.meshHong Kong - Epidemiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Gamma - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshRecombinant Proteinsen_US
dc.subject.meshVirus Replication - Drug Effectsen_US
dc.titleA randomised controlled trial of recombinant interferon-γ in Chinese patients with chronic hepatitis B virus infectionen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/jmv.1890340310-
dc.identifier.pmid1919540-
dc.identifier.scopuseid_2-s2.0-0025916176en_US
dc.identifier.volume34en_US
dc.identifier.issue3en_US
dc.identifier.spage184en_US
dc.identifier.epage187en_US
dc.identifier.isiWOS:A1991FZ47800009-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridChung, HT=7404007053en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats